Updates are available Correction dated 2026-02-18

Article History

Received: 5 March 2024

Accepted: 11 February 2025

First Online: 27 March 2025

Change Date: 18 February 2026

Change Type: Update

Change Details: The original online version of this article was revised: The Original article has been updated

Change Date: 18 February 2026

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s10549-026-07896-7

Declarations

:

: ADM reports institutional research support from Pfizer (Inst), Genetech (Inst), Novartis (Inst), NeoGenomics (Inst); honoraria from Fox Chase Cancer Center SABCS review 2024, Fox Chase Cancer Center SABCS review 2023, 3rd Annual Perspectives in Breast Cancer Care-Medscape 2023, 21st Annual International Congress on the Future of Breast Cancer® West San Deigo 2022, OncLive Institutional Perspectives in Cancer: Breast Cancer 2022, University Of Kanas City Post San Antonio Review 2022, ASCO 2021 Breast Cancer Highlights 2021. NZ reports honoraria from Lilly, Gilead, Pfizer, Eisai, AstraZeneca, Novartis; travel support for educational meeting attendance from Pfizer, Lilly and Novartis; participation on Advisory board for DMC; leadership for Scientific Advisory Committee Chair. JLreports honoraria from Novartis, Eli Lilly, Merck, Astra Zeneca, Daiichi Sanko, Exact Science, Gilead. GP reports research funding from Amgen, Roche,Accord, Lilly, Novartis, Seagen, Gilead, Daiichi, Menarini, Pfizer, MSD, Merck; honoraria from Amgen, Roche, Accord, Pfizer, Lilly, Merck, Daiichi, Menarini, Novartis, Seagen, MSD, and Gilead; consulting for Pfizer, Amgen, Lilly, Novartis, Merck, Daiichi, Roche, Gilead, MSD, Menarini, and Seagen; payment for expert testimony from Amgen, Roche,Accord, Lilly, Novartis, Seagen, Gilead, Daiichi, Menarini, Pfizer, MSD, Merck; travel support from Amgen, Roche,Accord, Lilly, Novartis, Seagen, Gilead, Daiichi, Menarini, Pfizer, MSD, Merck. KG reports honoraria from Eli Lilly, Pfizer, Novartis; participation in an advisory board for Eli Lilly, Pfizer, Novartis. DE reports honoraria from AstraZeneca, Daiichi-Sankyo, Gilead, Lilly, MSD, Menarini, Novartis, Pfizer, Roche, Seagen, Sirius Medical; Support for attending meetings/travel from AstraZeneca, Daiichi-Sankyo, Pfizer, Roche; participation on an advisory board for AstraZeneca, Daiichi-Sankyo, Gilead, Lilly, MSD, Menarini, Novartis, Pfizer, Roche, Seagen, Sirius Medical. GZ reports a leadership role in Immunomica S.r.l. TT reports research funding from Pfizer, AstraZeneca, Astellas Pharma, Genentech/Roche, Daiichi Sankyo, and Ayala Pharmaceuticals; consulting fees from Genentech/Roche, Pfizer, AstraZeneca, Merck, Daiichi Sankyo, Gilead Sciences, Novartis, GlaxoSmithKline, GE Healthcare, bioTheranostics, Hengrui Pharmaceuticals, G1 Therapeutics, Tersera, Stemline Therapeutics, Exact Sciences; participation on an advisory board for Genentech/Roche, I-SPY; and leadership for ASCO Breast Cancer Guideline Advisory Group (Co-Chair) and Chemo Foundation Symposium (Co-Chair). MMJ reports consulting fees from AstraZeneca, Lilly, MSD, Novartis, and Pfizer; honoraria from AstraZeneca, MSD, and Lilly. TH reports research funding from Takeda Onocolgy and consulting for Puma Biotechnology (Inst). AC reports honoraria from Olema Steering Committee; support for attendance/travel from San Antonio Breast Cancer Symposium by Olema; and leadership as Vice Chair for Breast Cancer Research Centre. AER reports consulting fees from Lilly, Seagen, and Gilead; honoraria from Pfizer, Lilly, Novartis, AZ/Daiichi-Sankyo, MSD, and Zuellig Pharma. AW reports research funding from Genentech (Inst), Merck Sharp & Dohme (Inst), Array BioPharma (Inst); he has been named as inventor on one or more issued patents or pending patent applications relating to methylation in breast cancer, and has assigned his rights to Johns Hopkins University (JHU), and participates in a royalty sharing agreement with JHU. WFS reports patent planned/issued/pending for genomic predictor of sensitivity to endocrine therapy for breast cancer and stock in Delphi Diagnostics. JJPL reports honoraria from Seattle Genetics, Novartis, Pfizer, AstraZeneca/ Daiichi Sankyo, Lilly, and Roche; advisory roles with Seattle Genetics, Novartis, AstraZeneca/ Daiichi Sankyo, Pierre Fabre, and Roche. DS reports honoraria from MSD, AZ, Gilead; participation on a Data Safety Monitoring Board for MSD. AB reports consulting fees from Astrazeneca, Pfizer, Novartis, Lilly, Genentech/Roche, SeaGen, Daiichi Sankyo, Merck, Agendia, Sanofi, Puma, Myriad, Gilead. MB-E reports personal fees from Pfizer, Novartis, and Lilly, outside the submitted work; and travel expenses from Pfizer and Roche. TF reports research support from Pfizer (Inst), AstraZeneca (Inst), Novartis (Inst), and Veracyte; royalties/licenses from UpToDate; consulting fees from Affibody; honoraria from Gilead, Pfizer, Roche, AstraZeneca; receipt for equipment/material/drugs/i.e. from AstraZeneca, Novartis, Veracyte, and Pfizer. YN reports honoraria from Novartis, Radius/Stemline, Astellas. GR reports consulting fees from Roche, Lilly, Pfizer, Novartis, Swixx, and AstraZeneca; honoraria from Novartis and Roche; support for attending meetings/travel from Swizz, Pfizer, and Roche. CFS reports grants and honoraria by Amgen, Daiichi Sankyo, Eli Lilly, Novartis, AstraZeneca, Pfizer, Roche, Seagen, Gilead, MSD. KM reports funding of study and partial support of salary from Pfizer. OM reports research funding from Pfizer; consulting fees from Grupo Oncoclinicas (Brazil); honoraria from Astra Zeneca, Merck, and Sanofi. TG reports research support from Pfizer. EL is employed by and a stockholder of Pfizer. AHP reports royalties from UpToDate Royalties. LAC reports other uncompensated financial/nonfinancial interests from Lilly, Seattle Genetics, Novartis, Genentech/Roche, and GSK. DH reports funding of study and partial support of salary from Pfizer. CF reports funding of study and partial support of salary from Pfizer. ELM reports a consulting role with Lilly, Novartis, AstraZeneca and Gilead. MG reports funding of study from Pfizer; consulting fees from EPG Health and MSD; honoraria from Amgen, AstraZeneca, Daiichi Sankyo, Eli Lilly, Menarini, Novartis, Pierre Fabre; payment for expert testimony from Eli Lilly and Veracyte; non-paid participation on an advisory board for ATNEC trial; and leadership in ABCSG. The remaining authors declare no competing interests.

: This study was conducted in line with the principles of the Declaration of Helsinki. The research protocol was approved by local or central institutional boards or ethics committees. The trial was monitored throughout by an international independent data monitoring committee. Patients provided written informed consent before participating in the study.